| LBEPA04 | HIV-1-induced isoformic PD-1 undermines Env-specific B cell response | E-poster | Host immune responses, vaccines and immunotherapies |
| LBEPA05 | Preserved frequency and cytotoxicity of HIV-specific follicular CD8 T cells associates with reduced viral reservoir in individuals treated during primary HIV infection | E-poster | Host immune responses, vaccines and immunotherapies |
| LBEPA06 | Epigenetic associations with APOL1 nephropathy and kidney function in individuals of African ancestry with HIV | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| LBEPA07 | In-depth characterization of functional anti-Env antibody responses during early or late viral suppression with fostemsavir in treatment-experienced patients | E-poster | Host immune responses, vaccines and immunotherapies |
| LBEPA08 | HIV-infected macrophages can be made susceptible to antibody dependent cellular cytotoxicity by small molecule CD4 mimetics | E-poster | HIV virology |
| LBEPA09 | Recombination of “defective” proviruses to produce replication-competent HIV-1 | E-poster | HIV virology |
| LBEPB11 | Effectiveness of point of care testing in improving HIV early infant diagnosis access in 16 US Agency for International Development Nigeria-supported states | E-poster | Diagnostic and monitoring tools |
| LBEPB12 | Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks | E-poster | Clinical complications of HIV and antiretroviral therapy |
| LBEPB13 | Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B | E-poster | Co-infections (including opportunistic infections) |
| LBEPB14 | Epidemiological and clinical features of mpox in adults aged greater than 50 years in the United States of America, May 2022–April 2023 | E-poster | HIV and ageing |